Bleeding outcomes and factor utilization after switching to an extended half-life product for prophylaxis in haemophilia A in Austria

To prevent bleeding in severe haemophilia A [SHA, defined as factor VIII (FVIII) activity < 1%] regular prophylactic FVIII replacement therapy is required, and the benefits of factor products with extended half-life (EHL) over traditional standard half-life (SHL) are still being debated. We perfo...

Descripción completa

Detalles Bibliográficos
Autores principales: Ay, Cihan, Feistritzer, Clemens, Rettl, Joachim, Schuster, Gerhard, Vavrovsky, Anna, Perschy, Leonard, Pabinger, Ingrid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8217178/
https://www.ncbi.nlm.nih.gov/pubmed/34155229
http://dx.doi.org/10.1038/s41598-021-92245-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8217178/
https://www.ncbi.nlm.nih.gov/pubmed/34155229
http://dx.doi.org/10.1038/s41598-021-92245-5

Ejemplares similares